1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 食品ソース別スニペット
3.2. 診断別スニペット
3.3. 治療別スニペット
3.4. 販売チャネル別スニペット
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. アレルゲンフリー製品に対する需要の高まり
4.1.1.2. AI主導のイノベーション
4.1.2. 阻害要因
4.1.2.1. 診断と投薬の高コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. ロシア・ウクライナ戦争の影響分析
5.6. DMI意見
6. COVID-19分析
6.1. COVID-19の分析
6.1.1. COVID-19以前のシナリオ
6.1.2. COVID-19開催中のシナリオ
6.1.3. COVID-19後のシナリオ
6.2. COVID-19中の価格ダイナミクス
6.3. 需給スペクトラム
6.4. パンデミック時の市場に関連する政府の取り組み
6.5. メーカーの戦略的取り組み
6.6. 結論
7. 食品ソース別
7.1. はじめに
7.1.1. 食品ソース別の市場規模分析および前年比成長率分析（%）。
7.1.2. 市場魅力度指数、食品ソース別
7.2. 乳製品
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 鶏肉製品
7.4. ピーナッツ
7.5. 貝類
7.6. 小麦
7.7. その他
8. 診断別
8.1. はじめに
8.1.1. 診断別市場規模分析および前年比成長率分析（%） 8.1.2.
8.1.2. 市場魅力度指数（診断別
8.2. インストルメンツ*市場
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 消耗品
8.4. サービス
8.5. 試験
8.5.1. 生体内／皮膚
8.5.2. 試験管内
8.6. その他
9. 治療法別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）, 治療法別
9.1.2. 市場魅力度指数（治療法別
9.2. エピネフリン
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 抗ヒスタミン薬
9.4. 経口免疫療法
9.5. その他
10. 販売チャネル別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.1.2. 市場魅力度指数（流通チャネル別
10.2. 病院薬局
10.2.1. 序論
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. 小売薬局
10.4. オンライン薬局
11. 地域別
11.1. はじめに
11.1.1. 地域別市場規模分析および前年比成長率分析(%)
11.1.2. 市場魅力度指数、地域別
11.2. 北米
11.2.1. 序論
11.2.2. 主な地域別ダイナミクス
11.2.3. 市場規模分析および前年比成長率分析（%）、食品ソース別
11.2.4. 市場規模分析および前年比成長率分析（%）、診断別
11.2.5. 市場規模分析および前年比成長率分析（%）, 治療法別
11.2.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.2.7. 市場規模分析および前年比成長率分析（%）, 国別
11.2.7.1. 米国
11.2.7.2. カナダ
11.2.7.3. メキシコ
11.3. ヨーロッパ
11.3.1. はじめに
11.3.2. 主な地域別動向
11.3.3. 市場規模分析および前年比成長率分析（%）、食品ソース別
11.3.4. 市場規模分析および前年比成長率分析（%）、診断別
11.3.5. 市場規模分析および前年比成長率分析（%）, 治療法別
11.3.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.3.7. 市場規模分析および前年比成長率分析（%）, 国別
11.3.7.1. ドイツ
11.3.7.2. イギリス
11.3.7.3. フランス
11.3.7.4. イタリア
11.3.7.5. スペイン
11.3.7.6. その他のヨーロッパ
11.4. 南米
11.4.1. はじめに
11.4.2. 地域別主要市場
11.4.3. 市場規模分析および前年比成長率分析（%）、食品ソース別
11.4.4. 市場規模分析および前年比成長率分析（%）、診断別
11.4.5. 市場規模分析および前年比成長率分析（%）, 治療法別
11.4.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.4.7. 市場規模分析および前年比成長率分析（%）, 国別
11.4.7.1. ブラジル
11.4.7.2. アルゼンチン
11.4.7.3. その他の南米諸国
11.5. アジア太平洋
11.5.1. はじめに
11.5.2. 主な地域別ダイナミクス
11.5.3. 食品ソース別の市場規模分析および前年比成長率分析（%） 11.5.4.
11.5.4. 市場規模分析および前年比成長率分析（%）、診断別
11.5.5. 市場規模分析および前年比成長率分析（%）, 治療法別
11.5.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11.5.7. 市場規模分析および前年比成長率分析（%）, 国別
11.5.7.1. 中国
11.5.7.2. インド
11.5.7.3. 日本
11.5.7.4. オーストラリア
11.5.7.5. その他のアジア太平洋地域
11.6. 中東・アフリカ
11.6.1. 序論
11.6.2. 主な地域別ダイナミクス
11.6.3. 市場規模分析および前年比成長率分析（%）、食品ソース別
11.6.4. 市場規模分析および前年比成長率分析（%）、診断別
11.6.5. 市場規模分析および前年比成長率分析（%）, 治療法別
11.6.6. 市場規模分析および前年比成長率分析（%）：流通チャネル別
12. 競合情勢
12.1. 競争シナリオ
12.2. 市場ポジショニング／シェア分析
12.3. M&A分析
13. 企業プロフィール
13.1. Astellas Pharma, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Aimmune Therapeutics
13.3. Meridian Medical Technologies
13.4. ALK-Abelló Ltd
13.5. Medeca Pharma AB
13.6. bioMeriux SA
13.7. Omega Diagnostics Group PLC
13.8. HYCOR Biomedical
13.9. HOB Biotech Group Corp Ltd.
13.10. Cambridge Allergy Ltd
リストは網羅的ではありません
14. 付録
14.1. 会社概要とサービス
14.2. お問い合わせ
Global Food Allergy Market reached US$ 40.16 billion in 2023 and is expected to reach US$ 60.19 billion by 2031, growing with a CAGR of 5.19% during the forecast period 2024-2031.
The World Allergy Organization has documented a worldwide rise in the incidence of food allergies. Eggs, milk, wheat, fish and tree nuts are among the most prevalent allergies. Notably, seafood allergies are more prevalent in Asia than to Western nations. The market growth is linked to heightened awareness, unfulfilled medical demands and the launch of novel products.
Advanced diagnostic techniques, such as refined blood assays, skin prick tests and molecular diagnostics, promote allergy identification by augmenting precision and expediency. The global market for food allergy diagnostics and therapies exhibits favorable development potential. The prospects arise from the escalating demand for cost-effective treatment alternatives, developments in diagnostic technologies, the introduction of novel products such as epinephrine auto-injectors and the rising incidence of food allergies worldwide.
It is essential to tackle challenges, such as elevated medicine expenses, to guarantee ongoing market growth. The increase in financing for allergy treatments is driving progress in research and the availability of novel medications. In September 2022, COUR Pharmaceuticals successfully concluded a funding round of US$ 30 million, including Alpha Wave Ventures as a principal investor.
Dynamics
Rising Demand for Allergen-Free Products
The global rise in individuals circumventing allergens in food and beverages—approximately 500 million, with roughly 85 million in the US alone—indicates substantial growth potential in the food allergy market. In the last twenty years, the incidence of food allergies in American youths has escalated roughly fourfold compared to population growth. This phenomenon is not limited to US; evidence suggests a global rise in food allergies, especially in young children in both developed and developing countries.
Recent research by McKinsey & Company indicates that consumers, whether directly impacted by allergies or purchasing for someone who is, frequently encounter stress while navigating grocery aisles to evade allergens. Numerous individuals invest significant time analyzing product labels, with some even eschewing entire categories of products.
Moreover, these consumers often pay a premium for superior, allergen-free products, demonstrating a preference for smaller, allergy-aware firms over larger counterparts, while also seeking new product alternatives. In US, spending on allergen-free supermarket products above the average, with consumers allocating nearly US$ 19 billion yearly to alternatives or allergen-free items. This expenditure is expected to persist in its upward trajectory, highlighting the growth potential within the food allergy sector.
AI-Driven Innovations
The food allergy industry is expanding due to heightened awareness, mostly propelled by improvements in artificial intelligence (AI) technology. AI-driven solutions are improving awareness via accurate product labeling, ingredient assessment and tailored notifications for individuals with food allergies. The advancements enable individuals to promptly identify potential allergies in items, facilitating safe and informed decision-making.
AI-powered applications facilitate the scanning of labels and the analysis of substances, thereby enhancing allergen awareness and empowering individuals to effectively manage their dietary requirements—particularly those with severe, multiple or uncommon allergies who have difficulties in locating safe food alternatives. In addition to consumer items, AI-driven technologies including hyperspectral imaging, machine learning, computer vision and Fourier transform infrared spectroscopy are progressively employed in food service and production for allergen detection.
The non-invasive techniques facilitate the assessment of food quality and the identification of pollutants, thereby mitigating the risk of severe allergic reactions due to cross-contact in restaurants and processing facilities. As awareness of food allergens escalates, the food allergy market is poised for substantial expansion, with consumers and businesses alike emphasizing safety and transparency.
High Cost Of Diagnosis And Medication
The substantial expense associated with detecting and managing food allergies, especially peanut allergies, constitutes a considerable limitation on the food allergy industry. Research indicates that peanut allergies contribute an annual incremental healthcare cost of EUR 304-400 per individual, alongside supplementary expenses of EUR 794 for anaphylaxis treatment and EUR 470 for adrenaline auto-injector (AAI) prescriptions. For UK population, these expenses together total an estimated EUR 40–53 million annually. Such fees can restrict access to adequate diagnosis and continuous treatment, as individuals and healthcare institutions may contend with these additional financial pressures.
Rising prices can impede the implementation of preventative strategies, diagnostic procedures and innovative, possibly life-saving treatments. Individuals lacking adequate insurance or financial resources may neglect allergy testing and management, heightening their risk of severe reactions. This constraint affects both patients and hinders the growth of the food allergy market, as elevated costs diminish the accessibility and demand for sophisticated diagnostic equipment, treatments and allergen-free products, hence impeding market progress.
Segment Analysis
The global food allergy market is segmented based on food sources, diagnosis, treatment, distribution channel and region.
High Risk And Treatment Focus For Peanut Allergies
Peanut allergies dominate the food source segment due to the presence of potent allergenic proteins, including Ara h 1, Ara h 2 and Ara h 3, which are known for their ability to trigger severe allergic reactions. These proteins are particularly resilient, resisting both heat and digestion, which increases the likelihood of a reaction even in trace amounts. Peanut allergy is especially dangerous, as it can cause anaphylaxis—a severe, life-threatening allergic response—often with very small exposure to the allergen, making peanuts one of the most high-risk allergens globally.
This dominance is further underscored by the fact that peanut allergy is currently the only food allergy with an FDA-approved treatment, Palforzia, highlighting the seriousness and prevalence of peanut-related reactions. Other treatments, such as peanut oral immunotherapy, are in use to increase tolerance to peanut proteins but remain non-FDA-approved. This specialized treatment focus for peanut allergies, combined with the high-risk profile of peanut proteins, positions peanuts as a leading and particularly challenging subsegment in the food allergy market.
Geographical Penetration
Advancements in North America Diagnosis and Treatment
North America is a developed region characterized by substantial healthcare expenditure. It commands the global market owing to the increasing recognition of potential in allergy therapeutics. Consequently, American corporations are allocating resources to the research and development of anti-allergenic pharmaceuticals. Furthermore, emerging competitors are launching innovative items, resulting in heightened competition among manufacturers.
The significant prevalence of food allergies in US stimulates the need for better diagnosis and effective treatment solutions. US healthcare system is a market leader, recognized for its sophisticated infrastructure, extensive access to medical services and thorough allergy testing and treatments. Advancements in treatment have significantly contributed to market growth and development. Oral immunotherapy presents significant market potential.
Recently, US Food and Drug Administration (FDA) approved Palforzia for the treatment of peanut allergy in children. This oral immunotherapy seeks to mitigate allergic responses, including anaphylaxis, resulting from inadvertent peanut exposure. It is appropriate for children between the ages of four and seventeen who have a verified diagnosis of peanut allergy.
Competitive Landscape
The major global players in the market include Astellas Pharma, Inc., Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abelló Ltd, Medeca Pharma AB, bioMeriux SA, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Corp Ltd. and Cambridge Allergy Ltd.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict has intensified the worldwide food crisis, resulting in heightened awareness and demand for allergy testing as food insecurity amplifies worries regarding the safety of accessible food. Furthermore, logistical obstacles have postponed the distribution of allergy testing kits and associated diagnostic instruments, constraining market expansion in impacted areas.
Conversely, the persistent issue has prompted an escalation in governmental and humanitarian initiatives to bolster healthcare infrastructure in impacted regions, encompassing food allergy detection. Nonetheless, healthcare systems have been overwhelmed and resources are frequently redirected to urgent humanitarian requirements, so impeding the broad availability and accessibility of allergy diagnostic services. This has led to a heterogeneous effect on market expansion, presenting constraints in certain sectors while offering development prospects in others.
Food Source
• Dairy Products
• Poultry Products
• Peanuts
• Shellfish
• Wheat
• Others
Diagnosis
• Instruments
• Consumables
• Services
• Tests
o In Vivo/Skin
o In Vitro
• Others
Treatment
• Epinephrine
• Antihistamines
• Oral Immunotherapy
• Others
Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In March 2024, Gold Standard Diagnostics introduced the inaugural product of the new allergy PowerLine tests: the SENSIStrip Gluten PowerLine Lateral Flow Device. The device features a sensitive detection technology utilizing a monoclonal antibody to identify gluten residues in food matrices, rinse water and swabs.
• In March 2024, ALS significantly enhanced and fortified its footprint in the Life Sciences sectors of Europe and US. ALS has acquired York Analytical Laboratories, located in Northeast US and Wessling Holding GmbH & Co., based in Western Europe.
• In February 2024, Mérieux NutriSciences inaugurated a state-of-the-art laboratory for food analysis in Maringá, Brazil. The newly established facility possesses federal CGRE/IMMETRO accreditation in accordance with NBR ISO/IEC 17025 standards, aimed at assisting the food industry in achieving quality benchmarks.
Why Purchase the Report?
• To visualize the global food allergy market segmentation based on food source, diagnosis, treatment, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the food allergy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global food allergy market report would provide approximately 70 tables, 68 figures and 203 pages
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Food Source
3.2. Snippet by Diagnosis
3.3. Snippet by Treatment
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Demand for Allergen-Free Products
4.1.1.2. AI-Driven Innovations
4.1.2. Restraints
4.1.2.1. High Cost Of Diagnosis And Medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Food Source
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
7.1.2. Market Attractiveness Index, By Food Source
7.2. Dairy Products*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Poultry Products
7.4. Peanuts
7.5. Shellfish
7.6. Wheat
7.7. Others
8. By Diagnosis
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
8.1.2. Market Attractiveness Index, By Diagnosis
8.2. Instruments*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Consumables
8.4. Services
8.5. Tests
8.5.1. In Vivo/Skin
8.5.2. In Vitro
8.6. Others
9. By Treatment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment
9.2. Epinephrine*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antihistamines
9.4. Oral Immunotherapy
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacy*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacy
10.4. Online Pharmacy
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. US
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Astellas Pharma, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Aimmune Therapeutics
13.3. Meridian Medical Technologies
13.4. ALK-Abelló Ltd
13.5. Medeca Pharma AB
13.6. bioMeriux SA
13.7. Omega Diagnostics Group PLC
13.8. HYCOR Biomedical
13.9. HOB Biotech Group Corp Ltd.
13.10. Cambridge Allergy Ltd
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us
❖ 世界の食物アレルギー市場に関するよくある質問(FAQ) ❖
・食物アレルギーの世界市場規模は？
→DataM Intelligence社は2023年の食物アレルギーの世界市場規模を401億6,000万米ドルと推定しています。
・食物アレルギーの世界市場予測は？
→DataM Intelligence社は2031年の食物アレルギーの世界市場規模を601億9,000万米ドルと予測しています。
・食物アレルギー市場の成長率は？
→DataM Intelligence社は食物アレルギーの世界市場が2024年～2031年に年平均5.2%成長すると予測しています。
・世界の食物アレルギー市場における主要企業は？
→DataM Intelligence社は「Astellas Pharma, Inc., Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abelló Ltd, Medeca Pharma AB, bioMeriux SA, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Corp Ltd. and Cambridge Allergy Ltd.など ...」をグローバル食物アレルギー市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
